Search - tctmd.com

Displaying 21 - 40 of 54

Sort: Relevancy | Date

News Daily News

New EXCEL Analysis Reignites Debate Over PCI for Left Main CAD

Michael O'Riordan

June 01, 2020

News Conference News ACC 2020

PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years

Michael O'Riordan

March 30, 2020

News Features

EXCEL Investigators Respond to Data Suppression Claims as Debate Erupts Online

Michael O'Riordan

December 12, 2019

News Daily News

Noninvasive Tests for Chest Pain: New Insight Into Who Benefits Most

Yael L. Maxwell

November 07, 2019

News Daily News

Believing SCOT-HEART: New Analysis Probes Plausible Mechanisms of Benefit

Shelley Wood

October 14, 2019

News Conference News TCT 2019

COAPT at 3 Years: Crossover Patients See Benefits From MitraClip

Shelley Wood

September 28, 2019

News Daily News

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

Michael O'Riordan

July 30, 2019

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

News Daily News

Irrational Exuberance or Evidence-Based Medicine: What Role for CT Angiography in Stable Chest Pain?

Michael O'Riordan

January 11, 2019

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Opinion Fellow Talk

A Look Back at TCT 2018: What I Took Away From the Meeting

Yashasvi Chugh, MD

October 23, 2018

News Opinion Editor's Corner TCT 2018

My Takeaways From TCT 2018: Sunglasses, Shadows, and the COAPT Eclipse

Shelley Wood

October 12, 2018

News Conference News TCT 2018

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Michael O'Riordan

October 02, 2018

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Daily News

Spin to Win: Results From Late-Breaking Meeting Trials Often Overstated

L.A. McKeown

May 15, 2018

News Features

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

Michael O'Riordan

March 23, 2018

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Daily News

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Will FDA’s Settlement With Amarin Weaken Agency Oversight of Off-Label Promotion?

Michael O'Riordan

March 09, 2016

Advertisement

New EXCEL Analysis Reignites Debate Over PCI for Left Main CAD

PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years

EXCEL Investigators Respond to Data Suppression Claims as Debate Erupts Online

Noninvasive Tests for Chest Pain: New Insight Into Who Benefits Most

Believing SCOT-HEART: New Analysis Probes Plausible Mechanisms of Benefit

COAPT at 3 Years: Crossover Patients See Benefits From MitraClip

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Irrational Exuberance or Evidence-Based Medicine: What Role for CT Angiography in Stable Chest Pain?

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

A Look Back at TCT 2018: What I Took Away From the Meeting

My Takeaways From TCT 2018: Sunglasses, Shadows, and the COAPT Eclipse

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Spin to Win: Results From Late-Breaking Meeting Trials Often Overstated

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Will FDA’s Settlement With Amarin Weaken Agency Oversight of Off-Label Promotion?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content